The stem cell-transplant technology developer, partly based on Stanford research, is going public through a reverse merger that will give it a $490m market capitalisation.

The Meituan Dianping, Tencent and Swiss Re-backed health insurance marketplace operator priced its offering at the top of its range.

Roche Venture Fund and Amgen will invest in the stem cell-transplant technology developer through a reverse merger transaction which will give it a $490m market capitalisation.

The Sanofi, Amgen, Alphabet, Novartis and PPD-backed clinical trials software producer is joining forces with publicly listed LifeSci Acquisition II Corp.

The Fosun-backed gene therapy developer had set terms for an offering set to raise between $135m and $149m on the Nasdaq Global Select Market.

The Takeda and Access Industries-backed oncology therapeutics developer is targeting an offering on the Nasdaq Global Market having previously raised $190m.

Talaris has raised $150m in an initial public offering almost two decades after being spun out of University of Louisville as Regenerx.

The corporate-backed lidar technology provider will now be valued at $1.52bn pre-acquisition rather than the $1.9bn figure when the deal was announced in February.

Barracuda Networks could be in line to exit the accountancy software producer, which had disclosed more than $31m in funding through 2015.

The UPMC-backed cancer biotherapeutics developer priced its shares in the middle of their range in its initial public offering.